Laurel Hill Congratulates Monique Allaire of AVEO Pharmaceuticals-Winner of Rising Star in Corporate Governance

NEW YORK CITY, NEW YORK--(Marketwire - Nov. 14, 2011) - The Laurel Hill Advisory Group ("Laurel Hill") congratulates Monique Allaire, Director of Investor Relations for AVEO Pharmaceuticals, for winning the award for Rising Star in Corporate Governance at the annual Corporate Governance Awards held on Thursday evening, November 10^th at Gotham Hall in New York City hosted by Corporate Secretary Magazine.

AVEO Pharmaceuticals emerged from Private Company status to Public Company status after an IPO in 2010. Monique Allaire, recognizing that expectations for publicly traded companies differ in many material aspects from expectations for private companies, reached out to legal, compensation and voting professionals to review the private company structures and present and recommend adjustments to AVEO's policies. Monique coordinated communication and supplied documents needed for a comprehensive review of the existing compensation plans and disclosures.

Ms. Allaire coordinated the presentation to the AVEO Board of Directors materials and commentary from outside counsel Wilmer Cutler Pickering Hale and Dorr LLP's Boston office and Laurel Hill Advisory Group, LLC, in a compressed time frame. This resulted in a well crafted and ultimately well received AVEO Proxy statement, Monique Allaire recognized the substantial differences between the needs and requirements of public versus private and acted on her own belief in the need to put a responsible foot forward regarding governance and compensation during a challenging year for all public companies. Monique is an effective advocate for adjustments to disclosure and practice, and enabled her company to hold its first public annual meeting as a member in good standing of public companies that recognize the need for good governance practices.

About AVEO

AVEO Pharmaceuticals is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients' lives. The company's lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types. AVEO's second most advanced product candidate, ficlatuzumab (AV-299), is a potent, functional anti-HGF/c-MET pathway antibody that is currently in Phase 2 clinical development. AVEO's proprietary Human Response Platform™ is designed to offer the company a unique advantage in cancer drug development and has provided a discovery engine for multiple therapeutic targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR.

About The Laurel Hill Advisory Group

The Laurel Hill Advisory Group is North America's only independent, cross border proxy solicitation firm. Independence means we focus solely on your interests, and are not subject to the conflicts that can arise within other proxy firms having a transfer agent ownership. Cross border operations allows us to effectively reach shareholders regardless of their location - Canada, US and globally. Our team's experience has resulted in Canada's best proxy contest win record for the past 3 years, and on both sides of the border we are regularly engaged on high profile, complex and contentious situations involving M&A, restructuring, and corporate governance issues. We focus on providing accurate intelligence along with tactical expertise and efficient execution which consistently produces industry leading results.